- Home
- TDAC vs ANNX Comparison
TDAC vs ANNX Comparison
Compare TDAC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDAC
- ANNX
- Stock Information
- Founded
- TDAC 2022
- ANNX 2011
- Country
- TDAC United States
- ANNX United States
- Employees
- TDAC N/A
- ANNX N/A
- Industry
- TDAC
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- TDAC
- ANNX Health Care
- Exchange
- TDAC NYSE
- ANNX Nasdaq
- Market Cap
- TDAC 221.0M
- ANNX 252.3M
- IPO Year
- TDAC 2024
- ANNX 2020
- Fundamental
- Price
- TDAC N/A
- ANNX $3.01
- Analyst Decision
- TDAC
- ANNX Strong Buy
- Analyst Count
- TDAC 0
- ANNX 4
- Target Price
- TDAC N/A
- ANNX $12.50
- AVG Volume (30 Days)
- TDAC 17.0K
- ANNX 1.5M
- Earning Date
- TDAC 01-01-0001
- ANNX 08-11-2025
- Dividend Yield
- TDAC N/A
- ANNX N/A
- EPS Growth
- TDAC N/A
- ANNX N/A
- EPS
- TDAC 0.16
- ANNX N/A
- Revenue
- TDAC N/A
- ANNX N/A
- Revenue This Year
- TDAC N/A
- ANNX N/A
- Revenue Next Year
- TDAC N/A
- ANNX N/A
- P/E Ratio
- TDAC $160.48
- ANNX N/A
- Revenue Growth
- TDAC N/A
- ANNX N/A
- 52 Week Low
- TDAC $10.00
- ANNX $1.29
- 52 Week High
- TDAC $10.29
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- TDAC N/A
- ANNX 70.42
- Support Level
- TDAC N/A
- ANNX $2.30
- Resistance Level
- TDAC N/A
- ANNX $2.53
- Average True Range (ATR)
- TDAC 0.00
- ANNX 0.20
- MACD
- TDAC 0.00
- ANNX 0.02
- Stochastic Oscillator
- TDAC 0.00
- ANNX 74.42
About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI
Translational Development Acquisition Corp is a newly organized blank check company.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.